Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete ...

Merck (NYSE:MRK) said a Phase 3 study of its drug Keytruda in the treatment of a certain type of ovarian cancer met its primary endpoint of progression-free survival, but not its secondary ...

Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of the year, accelerating the company’s efforts to protect its top ...

In extending patent protection for its primary cancer medication, Keytruda, Merck (NYSE:MRK) intends to introduce a subcutaneous form of it this year. It's important to also note that Merck is ...

The trial, which involved 93 patients across multiple sites in the US, Europe, and Australia, aims to evaluate the treatment's anti-tumor activity ... with Merck's KEYTRUDA® for treating certain ...